Fresenius SE & Co. KGaA

Investor Presentation • Sep 20, 2012

Sanford C. Bernstein – Strategic Decisions Conference

September 19, 2012

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE & Co. KGaA

Fresenius Group: Financial Results

Sales 5-year CAGR: 10%

EBIT5-year CAGR: 12%

Net Income5-year CAGR: 17%

Group financial results before APP-transaction-related special items

Fresenius: Attractive Long-term Shareholder Returns

19th consecutive dividend increase2011 proposal: +10%, €0.95 per share

Compounded annual total return 2002 − 2011

Source: Bloomberg; dividends reinvested

Fresenius Group: Financial Results

	1 l S a e s	2 E B I T	3 i N t e n c o m e
/ 2 H 1 1	€ 9 2 3 6 m ,	€ 0 1 4 4 m ,	€ 3 4 4 m
G h t t t t r o w a c o n s a n t c u r r e n c y r a e s	1 2 %	% 1 4	% 1 5
G h l t t t o a a c a r w u t c e n c a e s u r r y r	1 7 %	1 9 %	2 0 %

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

2Adjusted for one-time costs of €7 million in Q2 2012 related to the offer to the shareholders of RHÖN-KLINIKUM AG.

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA ‒ adjusted for a non-taxable investment gain at Fresenius Medical Care and for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG; 2011 before special items due to MEB and CVR accounting

Fresenius Group: Financial Results by Business Segment

/ 1 1 2 H	i F e s e n s r u d i l M C e c a a e r	i i F F e s e n s e s e n s r u r u b i l i K H a e o s		i F e s e n s r u d V a m e
l S a e s h G t o r w	\$ S 6 6 U 7 7 m , 1 9 %	€ 2 2 3 4 m , 1 3 %	€ 1 5 4 0 m , 1 9 %	€ 3 3 3 m 6 %
E B I T h G t o r w	\$ S 0 9 2 U 1 m , 1 4 %	€ 4 5 2 m 1 0 %	€ 1 5 1 m 2 3 %	€ 1 3 m 8 %

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

Fresenius Kabi: Update H1/12

• 9% organic sales growth exceeding outstanding H1/11, excellent contribution from all regions
• +10% outside North America
• +9% in North America
• U.S. I.V. drug shortage situation continued
• Shortage list July: 94 drugs, 31 marketed by Kabi (January 2012: 86 drugs, 28 marketed by Kabi)
• Acquisition of Fenwal creates a global leader in transfusion technology; provides ideal platform for future growth
• 2015 mid-term targets1 increased due to Fenwal acquisition: Sales ~€6 bn (before: ~€5.5 bn) EBIT >€1.1 bn (before: >€1 bn)

1At current exchange rates

Fresenius Helios: Update H1/12

• • 5.4% organic sales growth; 230 bps EBIT margin increase to 11.9% in established clinics – excellent operating results and one-time gain
• • Integration of acquired hospitals Duisburg and Damp on track
• • Hospital privatization market update:
• Privatized hospital revenue 2012 YTD: ~€450 m significantly exceeding FY/11 (~€365 m) and FY/10 (~€230 m)
• Projects >€250 million revenue pending
• • Announced September 3rd not to submit a new RHOEN-KLINIKUM AG takeover offer for the time being

Fresenius Vamed: Update H1/12

• Sales and EBIT in line with expectations and guidance
• Order intake in project business at €156 million; acceleration in H2/12 expected
• Acquisition of H.C. Hospital Consulting / Florence:
• • Italian market entry for maintenance / technical management of medical equipment
• • 2011 sales: approx. €30 million; consolidated as of Jan 1, 2012
• -Provider for approx. 130 health care facilities
• • More than 30 years of experience in Italian health care market

Q2 order intake: Turnkey project at San Fernando General Hospital – Republic of Trinidad and Tobago

Fresenius Group: 2012 Financial Outlook by Business Segment

i F r e s e n u s b i K a	1 l h S t a e s g o r w i E B I T m a r g n	9 % ~ 2 0 % 5 ~
i F e s e n s r u l i H e o s	1 l h S t a e s g o r w E B I T	3 % 5 % – € 3 0 € 3 2 0 ( d ) 1 m m u p p e r e n –
i F r e s e n u s d V a m e	S l h t a e s g r o w h E B I T t g o r w	% 0 % 5 1 – 5 % 1 0 % –
i F e s e n s r u i h B t o e c	E B I T	€ 2 5 € 3 0 m m ~ - – -

1 organic

Fresenius Group: 2012 Financial Outlook

1 h R t e v e n u e g r o w t t t a c o n s a n c u r r e n c y	1 2 % 1 4 % –
2 h i N t t e n c o m e g o r w t t t a c o n s a n c e n c u r r y	% 6 % 1 4 1 –
C a p e x	f % G l 5 o o p s a e s r u ~

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

2Net income attributable to shareholders of Fresenius SE & Co. KGaA ‒ adjusted for a non-taxable investment gain at Fresenius Medical Care

Outlook before one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG

Attachments

Fresenius Group: Profit and Loss Statement

€ m	/ / Q 2 1 2 H 1 1 2		h G Q t o r w	/ 2 1 2 Y Y o
			l t a c u a t r a e s	t t c o n s a n t r a e s
1 l S a e s	4 8 1 7 ,	9 2 3 6 ,	2 0 %	1 4 %
2 E B I T	9 7 7	0 1 4 4 ,	2 3 %	% 1 5
N i t t t e n e e s r	1 6 6 -	3 1 3 -	1 8 % -	1 1 % -
I t n c o m e a x e s	9 1 1 -	3 4 7 -	2 % 5 -	6 % 1 -
3 i N t e n c o m e	2 3 4	3 4 4	2 1 %	1 % 4

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

2Adjusted for one-time costs of €7 million in Q2 2012 related to the offer to the shareholders of RHÖN-KLINIKUM AG.

Net income attributable to shareholders of Fresenius SE & Co. KGaA ‒ adjusted for a non-taxable investment gain at Fresenius Medical Care and for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG, 2011 before special items due to MEB and CVR accounting

Fresenius Group: Cash Flow

€ m	/ Q 2 1 2	L T M 1 i M a g n r	/ Q 2 1 1	L T M 1 i M a g n r	h Y G t r o w Y o
i h l O C F t p e a n g a s o r w	5 9 8	1 2 3 %	3 7 2	1 0 8 %	6 1 %
C ( ) t a p e x n e	2 0 6 -	4 7 % -	1 4 5 -	4 3 % -	4 2 % -
C h l F F r e e a s o w ( b f d d d d ) i i t i i i e o r e a c q u s o n s a n v e n s	3 9 2	6 % 7	2 2 7	6 % 5	3 % 7
( ) A i i i t t c q u s o n s n e	0 0 1 -		5 9 7 -		8 3 %
d d D i i e n s v	3 0 5 -		2 8 8 -		2 2 % -
h l F C F r e e a s o w ( f d d d d ) i i i i i t t a e a c q s o n s a n e n s r u v	5 8 -	6 3 % -	6 5 8 -	3 1 % -	9 1 %

1Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

Cash Flow Development LTM

€ m	O t p e r a	i C F n g	C a p e x	( ) t n e	1 h l F C F r e e a s o w
	L T M H 1 / 1 2	L T M M i a r g n	L T M H 1 / 1 2	L T M M i a r g n	L T M H 1 / 1 2	L T M M i a r g n
	5 4 5	1 2 9 %	( ) 1 8 1	( ) 4 3 %	3 6 4	8 6 %
	2 2 5	8 % 7	( ) 1 6 5	( ) % 5 7	8 7	3 3 0 %
	3 2 -	4 2 % -	( ) 8	( ) 1 1 %	4 0 -	5 3 % -
Co / te rp or a he O t r	1 -	/ n a	( 3 ) 1	/ n a	1 4 -	/ n a
l. C F M ex c	7 6 4	2 1 0 4 %	( ) 3 6 7	( ) 4 6 %	3 9 7	2 5 8 %
G ro up	2 1 7 5 ,	3 1 2 %	( 8 ) 2 4	( ) 4 7 %	3 1 5 1 ,	6 % 7

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 4.4% excluding €41 million of capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

	J 3 0 n u , 2 0 1 2	D 3 1, e c 2 0 1 1
b ( € ) D t e m \$ f he 5 2 % U S t re o de in d te no m a	2 0 3 1 5 ,	9 9 9 7 ,
d b ( ) N € t t e e m	1 0 0 6 8 ,	9 1 6 4 ,
d b / N E B I T D A t t e e	1, 2 2 7 5	2 8 3
/ E B I T D A I t t n e r e s	8 5	6 1

Net debt/EBITDA

1Pro forma Liberty Dialysis Holdings, Inc. and Damp Group

2Before one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG

Debt excludes Mandatory Exchangeable Bonds which came to maturity on August 14, 2011

Fresenius Kabi: Strong Organic Sales Growth

€ m	/ H 1 1 2	/ H 1 1 1	i O g a n c r G h t o r w
f h I i T n s o n e a p u r y	5 0 0	4 4 3	1 0 %
I. V D g s r u	8 4 7	3 2 7	0 % 1
l l C i i N i i t t n c a o n u r	6 4 8	5 6 0	1 2 %
d l / M i D i e c a e v c e s f h l T i T a n s s o n e c n o o g r u y	2 3 9	2 3 6	1 %
l l T t o a s a e s	2 2 3 4 ,	1 9 7 1 ,	9 %

Fresenius Kabi: Strong Organic Sales Growth

€ m	/ H 1 1 2	/ H 1 1 1	i O r g a n c h G t r o w
E o p e u r	9 7 4	9 0 9	6 %
h N A i t o r m e r c a	6 0 9	5 1 9	9 %
f A i P i i s a a c c -	4 1 5	3 3 2	1 5 %
/ f L i A i A i t a n m e r c a r c a	2 3 6	2 1 1	% 1 4
l l T t o a s a e s	2 2 3 4 ,	9 1 7 1 ,	9 %

Fresenius Kabi: Excellent EBIT Improvement

€ m	/ H 1 1 2	/ H 1 1 1	h G t o r w
E o p e u r M i a g n r	1 9 2 1 9 7 %	1 9 1 2 1. 0 %	1 %
h N A i t o m e c a r r M i a g n r	2 5 0 4 1. 1 %	2 0 0 3 8. 5 %	2 5 %
f f / / A i P i i L i A i A i t s a a c c a n m e c a c a r r - i M a r g n	3 1 1 2 0. % 1	0 1 4 9 2 % 1	2 6 %
d C C R & D t t o r p o r a e a n o r p o r a e	1 2 1 -	8 4 -	4 4 % -
l T E B I T t o a	2 4 5	4 1 1	0 % 1
i M a r g n	2 0 2 %	2 0 9 %

Fresenius Helios: Strong Sales and EBIT Growth

€ m	/ 1 1 2 H	/ 1 1 1 H	h G t o r w
l l T t o a s a e s	1 5 4 0 ,	1 2 9 3 ,	1 9 %
E B I T
b l h d l f l i i i i E t t s a s e c n c p o o o r M i a r g n	1 6 2 1 1. 9 %	1 2 4 9 6 %	3 1 %
/ i i i i i A t D t t c q s o n s e s e s u v u r ( l i d i / d l i d i 1 ) t t < c o n s o a o n e c o n s o a o n y r	1 1 -	1 -
l T t E B I T o a i M a g n r	1 5 1 9 8 %	1 2 3 9 5 %	2 3 %

Fresenius Helios: 2011 Clinic Development Plan

	i f l i Y t e a s n p o o o r r
	1 <	1	2	3	4	5	5 >	l T t o a
f l N i i o. o c n c s	1	1	-	6	4	7	2 5	4 3
( ) R € e e n e m v u	1 6	3 4	-	1 8 3	2 7 1	1 7 2	1, 6 6 2	2, 3 3 6
T t
a g e r
( ) E B I T D A i % m a g n r	-	3. 0	6. 0	9 0	1 2. 0	1 5. 0	1 5. 0
( ) E B I T D A € m	-	1. 0	-	1 6. 4	3 2. 5	2 5. 7	2 4 9 2	3 2 4 8
d R t e p o r e
( % ) E B I T D A i m a r g n	-	2. 6 -	-	2. 9	3. 2 1	2 1 1.	6. 9 1	1 4 4
( € ) E B I T D A m	3. 2 -	0. 9 -	-	3 5.	3 5. 7	9 2 1	2 8 0. 3	3 3 6. 4
f l N i i t t > o. o c n c s a r g e	-	-	-	3	2	3	1 5	2 3
f l i i N t t < o. o c n c s a r g e	-	1	-	3	2	4	0 1	2 0

IFRS

Fresenius Helios: Performance Indicators

	/ 2 H 1 1	/ H 1 1 1	C h a n g e
f h l N i t o o o s p a s A l i i t c u e c a r e c n c s - l i i P t- t o s a c u e c a r e c n c s -	7 5 5 1 2 4	1 6 5 4 5 2 0	% 1 5 1 3 % 2 0 %
f b d N o o e s l A i i t c e c a e c n c s u r - l P i i t- t o s a c u e c a r e c n c s -	2 3 6 1 5 , 1 8, 8 2 4 4, 7 9 1	1 2 0 2 1 1 , 1 6, 6 9 0 3, 4 2 2	% 1 7 1 3 % 4 0 %
2 d A i i m s s o n s ( ) A i i t t t c e c a e n p a e n u r -	3 9 9 3 6 1,	3 2 1 4, 7 4	1 5 %
2 O c c p a n c u y P t- t o s a c e c a e u r -	8 5 %	7 9 %
f l h ( d ) A t t e a g e e n g o s a a s v r y y A t e a e c u c r - 2 P t- t o s a c u e c a r e -	6. 7 2 7. 6	6. 7 2 9 6

1 Dec 31, 2011

2Clinics in Germany

Fresenius Vamed: Sales Growth and EBIT in line with Expectations

€ m	/ H 1 1 2	/ H 1 1 1	h G t r o w
b P j i t o e n e r c u s s s	8 1 4	2 0 2	9 % -
b S i i e c e s n e s s r v u	1 4 9	1 1 1	3 4 %
l l T t o a s a e s	3 3 3	3 3 1	6 %
l T E B I T t o a	1 3	1 2	8 %
i M a g n r	3 9 %	3 8 %
1 d i k O t r e r n a e	1 5 6	1 6 4	5 % -
1 d b k l O r e r a c o g	8 1 6	2 8 4 5	3 % -

Share Information

Share key facts

Number of shares¹ 177,813,382 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Exchange OTC-market Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Structure Sponsored Level I ADR

1as of August 31, 2012

Financial Calendar

• 31.10.2012 Report on 1st 3rd quarter 2012
• 26.02.2013 Report on Fiscal Year 2012
• 30.04.2013 Report on 1st quarter 2013
• 17.05.2013 Annual General Meeting, Frankfurt/Main
• 30.07.2013 Report on 1st half 2013
• 05.11.2013 Report on 1st 3rd quarter 2013

Contact

• Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA
• Telephone: +49 6172 608-2485 e-mail: Birgit.Grund@fresenius.com

For further information and current news: http://www.fresenius.com